American Century Companies
VERV

American Century Companies’s Verve Therapeutics VERV Stock Holding History

American Century Companies’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-169,168
Closed -$1.9M – 2883
2025
Q2 		$1.9M Buy
169,168
+18,292
+12% +$104K ﹤0.01% 2047
2025
Q1 		$690K Buy
150,876
+23,412
+18% +$157K ﹤0.01% 2389
2024
Q4 		$719K Buy
127,464
+13,916
+12% +$78.5K ﹤0.01% 2377
2024
Q3 		$550K Buy
113,548
+21,048
+23% +$122K ﹤0.01% 2447
2024
Q2 		$451K Buy
92,500
+16,525
+22% +$104K ﹤0.01% 2480
2024
Q1 		$1.01M Buy
75,975
+29,848
+65% +$396K ﹤0.01% 2149
2023
Q4 		$643K Buy
46,127
+19,297
+72% +$239K ﹤0.01% 2267
2023
Q3 		$356K Buy
26,830
+8,680
+48% +$140K ﹤0.01% 2399
2023
Q2 		$340K Buy
+18,150
New +$302K ﹤0.01% 2358

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

American Century Companies's VERV Position: Q3 2025 in Review

American Century Companies sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 169,168 shares — an estimated $1.9M sold.

American Century Companies first reported a position in VERV in Q2 2023 and held it in 9 quarters. The position peaked at $1.9M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • American Century Companies reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • American Century Companies sold 169,168 Verve Therapeutics shares in Q3 2025, an estimated $1.9M.
  • American Century Companies first reported a position in Verve Therapeutics in Q2 2023 and held it in 9 quarters.
  • American Century Companies's Verve Therapeutics position peaked at $1.9M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on American Century Companies's 13F filing for Q3 2025, filed 12 Nov 2025.